We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
+3.88%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$10.6M
(+7.6%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
7.76%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
53
New
7
Increased
21
Reduced
13
Closed
7
Avg Time Held
4.4
quarters
Top 10 Avg Time Held
0.8
quarters
Top 20 Avg Time Held
0.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JD.com
JD
|
+$10.5M |
| 2 |
Heron Therapeutics
HRTX
|
+$2.69M |
| 3 |
TG Therapeutics
TGTX
|
+$2.69M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$2.57M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$2.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$2.78M |
| 2 |
Puma Biotechnology
PBYI
|
+$2.66M |
| 3 |
ABLX
Ablynx NV
ABLX
|
+$2.63M |
| 4 |
Travere Therapeutics
TVTX
|
+$2.57M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.63% |
| 2 | Financials | 29.15% |
| 3 | Consumer Discretionary | 10.46% |
| 4 | Industrials | 2.95% |
| 5 | Communication Services | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class A
BRK.A
$1.11T
| $33M | 21.9% |
117
| – | – |
2016 Q4
6 quarters
|
|
|
2
JD.com
JD
$36.6B
| $15.5M | 10.28% |
397,578
+273,088
| +219% | +$10.5M |
2017 Q4
2 quarters
|
|
|
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.56M | 2.36% |
89,951
+1,489
| +2% | +$47.2K |
2017 Q3
3 quarters
|
|
|
GHDX
4
DELISTED
Genomic Health, Inc.
GHDX
| $3.55M | 2.36% |
70,470
-9,121
| -11% | -$362K |
2015 Q1
13 quarters
|
|
|
5
Heron Therapeutics
HRTX
$77.1M
| $3.28M | 2.18% |
+84,475
| New | +$2.69M |
2018 Q2
0 quarters
|
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.1M | 2.06% |
46,734
-1,345
| -3% | -$77K |
2015 Q1
13 quarters
|
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $3.08M | 2.05% |
69,746
+6,247
| +10% | +$257K |
2016 Q4
6 quarters
|
|
|
ABMD
8
DELISTED
Abiomed Inc
ABMD
| $2.89M | 1.92% |
+7,065
| New | +$2.56M |
2018 Q2
0 quarters
|
|
|
TFCF
9
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $2.86M | 1.9% |
58,010
+792
| +1% | +$31K |
2016 Q4
6 quarters
|
|
10
BioMarin Pharmaceuticals
BMRN
$10.6B
| $2.84M | 1.89% |
30,190
-633
| -2% | -$55.4K |
2015 Q1
13 quarters
|
|
|
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
| $2.84M | 1.89% |
182,043
+9,377
| +5% | +$142K |
2017 Q2
4 quarters
|
|
|
ECYT
12
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $2.83M | 1.88% |
+205,295
| New | +$2.44M |
2018 Q2
0 quarters
|
|
13
Neurocrine Biosciences
NBIX
$14.5B
| $2.83M | 1.88% |
28,819
-1,906
| -6% | -$171K |
2017 Q2
4 quarters
|
|
|
MYOV
14
DELISTED
Myovant Sciences Ltd.
MYOV
| $2.81M | 1.87% |
123,055
-53,332
| -30% | -$1.16M |
2017 Q2
4 quarters
|
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.74M | 1.82% |
22,081
+288
| +1% | +$33.7K |
2015 Q2
12 quarters
|
|
16
Ascendis Pharma A/S
ASND
$15.1B
| $2.7M | 1.79% |
40,528
-6,405
| -14% | -$421K |
2016 Q4
6 quarters
|
|
17
Incyte
INCY
$22.9B
| $2.67M | 1.77% |
39,831
+9,384
| +31% | +$642K |
2015 Q1
13 quarters
|
|
18
Wave Life Sciences
WVE
$682M
| $2.6M | 1.72% |
67,925
+20,039
| +42% | +$863K |
2016 Q4
6 quarters
|
|
19
Alnylam Pharmaceuticals
ALNY
$31.1B
| $2.59M | 1.72% |
26,256
+4,940
| +23% | +$490K |
2017 Q2
4 quarters
|
|
|
20
TG Therapeutics
TGTX
$8.48B
| $2.57M | 1.71% |
+195,463
| New | +$2.69M |
2018 Q2
0 quarters
|
|
21
InflaRx
IFRX
$236M
| $2.5M | 1.66% |
77,554
-13,207
| -15% | -$456K |
2018 Q1
1 quarter
|
|
22
KKR & Co
KKR
$81.6B
| $2.47M | 1.64% |
99,559
+4,222
| +4% | +$93.8K |
2017 Q4
2 quarters
|
|
|
GBT
23
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.46M | 1.63% |
54,317
+12,707
| +31% | +$579K |
2017 Q2
4 quarters
|
|
|
LJPC
24
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $2.43M | 1.61% |
83,163
+5,828
| +8% | +$180K |
2017 Q2
4 quarters
|
|
25
Bread Financial
BFH
$3.86B
| $2.42M | 1.61% |
13,031
+2,178
| +20% | +$372K |
2016 Q4
6 quarters
|
|
Similar funds
WH
CPW
NWS
SGM
CI
SA
SH
HA
Emory University's Q2 2018 Portfolio in Review
As of Q2 2018, Emory University held 53 positions worth $151M, up 7.6% from $140M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Emory University deployed $11.7M of net new capital in Q2 2018, opening 7 new positions and adding to 21 existing holdings. Its largest new stake was Heron Therapeutics: 84,475 shares worth $3.28M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 57% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Myovant Sciences Ltd., an estimated $1.16M trimmed.
- Emory University's largest Q2 2018 buy was Heron Therapeutics: 84,475 shares worth $3.28M.
- Emory University added most to JD.com in Q2 2018, an estimated $10.5M increase.
- Emory University's biggest Q2 2018 reduction was Myovant Sciences Ltd., cutting an estimated $1.16M.
- Emory University fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $2.78M.
- Emory University's ten largest holdings make up 49% of its $151M portfolio in Q2 2018.
- Emory University opened 7 new positions and closed 7 in Q2 2018.
- Emory University's portfolio value rose 7.6% quarter-over-quarter to $151M.
Based on Emory University's 13F filing for Q2 2018, filed 14 Aug 2018.